Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01748721 · ClinicalTrials.gov registry record · Phase 1
MORAb-004 in Treating Young Patients With Recurrent or Refractory Solid Tumors or Lymphoma
A Phase 1 study, sponsored by Morphotek.
- Completed
- Registry status
- Phase 1
- Development phase
- 27
- Enrollment target
NCT01748721: Completed Phase 1 study, sponsored by Morphotek.
NCT01748721 is a Phase 1 study that has completed, run by Morphotek. The registered enrollment target is 27 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (55% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01748721, a Phase 1 study, has completed, sponsored by Morphotek.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 27 participants
- Enrollment target
Study Summary
This phase I trial studies the side effects and best dose of MORAb-004 in treating young patients with recurrent or refractory solid tumors or lymphoma. Monoclonal antibodies, such as MORAb-004, can block cancer growth in different ways. Some block the ability of cancer to grow and spread. Others find cancer cells and help kill them or carry cancer-killing substances to them
Interventions
- OTHER laboratory biomarker analysis
- OTHER pharmacological study
- BIOLOGICAL anti-endosialin/TEM1 monoclonal antibody MORAb-004
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 27 participants |
| Start Date | 2013-11 |
| Est. Completion | 2015-05 |
| Phase | Phase 1 |
What the finished NCT01748721 record still lists
NCT01748721 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 27 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (55% lower).
The record links to 0 conditions, and to 3 interventions - of which laboratory biomarker analysis is the first listed.
NCT01748721 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01748721 about?
NCT01748721 is a clinical study titled "MORAb-004 in Treating Young Patients With Recurrent or Refractory Solid Tumors or Lymphoma". This phase I trial studies the side effects and best dose of MORAb-004 in treating young patients with recurrent or refractory solid tumors or lymphoma. Monoclonal antibodies, such as MORAb-004, can block cancer growth in different ways. Some block the ability of cancer to grow and spread. Others fi...
What is the current status of trial NCT01748721?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 27 participants. The study started on 2013-11. Estimated completion is 2015-05.
What interventions are being tested in trial NCT01748721?
The interventions under investigation include: laboratory biomarker analysis (OTHER), pharmacological study (OTHER), anti-endosialin/TEM1 monoclonal antibody MORAb-004 (BIOLOGICAL).
Who is sponsoring clinical trial NCT01748721?
This trial is sponsored by Morphotek, which has 20 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01748721's enrollment target sits among peer trials
27 1463rd of 2000 higher than 519 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00912041 · 27 participants · NA
BrainGate2: Feasibility Study of an Intracortical Neural Interface System for Persons With Tetraplegia
- NCT02847559 · 27 participants · Phase 2
Optune Delivered Electric Field Therapy and Bevacizumab in Treating Patients With Recurrent or Progressive Grade 2 or 3 Meningioma
- NCT03380195 · 27 participants · NA
Effects of Watermelon Juice on Heart Rate Recovery and Post-exercise Muscle Soreness
- NCT03384238 · 27 participants · Phase 1
Panitumumab-IRDye800 in Patients With Pancreatic Cancer Undergoing Surgery
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia